Immunovant Inc’s filing revealed that its Former Affiliate MARK S LEVINE acquired Company’s shares for reported $1.41 million on Feb 14 ’25. In the deal valued at $20.16 per share,69,763 shares were bought.
Then, MARK S LEVINE bought 29,196 shares, generating $570,437 in total proceeds.
Before that, Stout Jay S sold 2,195 shares. Immunovant Inc shares valued at $51,780 were divested by the Chief Technology Officer at a price of $23.59 per share. As a result of the transaction, Stout Jay S now holds 139,991 shares, worth roughly $2.85 million.
Wolfe Research downgraded its Immunovant Inc [IMVT] rating to a Peer perform from a an Outperform in a research note published recently. Oppenheimer also remained covering IMVT and reiterated its “an Outperform” recommendation on October 09, 2024. Oppenheimer started covering the stock on March 28, 2024. It rated IMVT as “an Outperform”.
Price Performance Review of IMVT
On Friday, Immunovant Inc [NASDAQ:IMVT] saw its stock jump 2.37% to $20.33. Over the last five days, the stock has lost -0.39%. Immunovant Inc shares have fallen nearly -17.92% since the year began. Nevertheless, the stocks have fallen -44.93% over the past one year. While a 52-week high of $39.55 was reached on 01/02/25, a 52-week low of $19.07 was recorded on 02/12/25. SMA at 50 days reached $24.18, while 200 days put it at $27.71.
Levels Of Support And Resistance For IMVT Stock
The 24-hour chart illustrates a support level at 19.98, which if violated will result in even more drops to 19.64. On the upside, there is a resistance level at 20.58. A further resistance level may holdings at 20.84. The Relative Strength Index (RSI) on the 14-day chart is 38.93, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.97, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.77%. Stochastics %K at 17.34% indicates the stock is a buying.
How much short interest is there in Immunovant Inc?
A steep rise in short interest was recorded in Immunovant Inc stocks on 2025-01-31, growing by 0.89 million shares to a total of 13.15 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 12.26 million shares. There was a rise of 6.76%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 13, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $50 price target.
